中国神经再生研究(英文版) ›› 2024, Vol. 19 ›› Issue (1): 16-21.doi: 10.4103/1673-5374.375299

• 综述:神经损伤修复保护与再生 • 上一篇    下一篇

B型单胺氧化酶抑制剂在神经系统疾病中的应用:基于临床前研究结果的临床应用

  

  • 出版日期:2024-01-15 发布日期:2023-08-02

Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings

Marika Alborghetti1, Edoardo Bianchini1, 2, Lanfranco De Carolis1, Silvia Galli1, Francesco E. Pontieri1, 2, Domiziana Rinaldi1, 2, *   

  1. 1Neurology Unit, NESMOS Department, Faculty of Medicine & Psychology, Sapienza—University of Rome, Sant’Andrea University Hospital, Rome, Italy; 2Department of Clinical and Behavioral Neurology, IRCCS—Fondazione Santa Lucia, Rome, Italy
  • Online:2024-01-15 Published:2023-08-02
  • Contact: Domiziana Rinaldi, MD, domiziana.rinaldi@gmail.com or domiziana.rinaldi@uniroma1.it.

摘要:

https://orcid.org/0000-0002-8011-087X (Domiziana Rinaldi)

Abstract: Type-B monoamine oxidase inhibitors, encompassing selegiline, rasagiline, and safinamide, are available to treat Parkinson’s disease. These drugs ameliorate motor symptoms and improve motor fluctuation in the advanced stages of the disease. There is also evidence supporting the benefit of type-B monoamine oxidase inhibitors on non-motor symptoms of Parkinson’s disease, such as mood deflection, cognitive impairment, sleep disturbances, and fatigue. Preclinical studies indicate that type-B monoamine oxidase inhibitors hold a strong neuroprotective potential in Parkinson’s disease and other neurodegenerative diseases for reducing oxidative stress and stimulating the production and release of neurotrophic factors, particularly glial cell line-derived neurotrophic factor, which support dopaminergic neurons. Besides, safinamide may interfere with neurodegenerative mechanisms, counteracting excessive glutamate overdrive in basal ganglia motor circuit and reducing death from excitotoxicity. Due to the dual mechanism of action, the new generation of type-B monoamine oxidase inhibitors, including safinamide, is gaining interest in other neurological pathologies, and many supporting preclinical studies are now available. The potential fields of application concern epilepsy, Duchenne muscular dystrophy, multiple sclerosis, and above all, ischemic brain injury. The purpose of this review is to investigate the preclinical and clinical pharmacology of selegiline, rasagiline, and safinamide in Parkinson’s disease and beyond, focusing on possible future therapeutic applications.

Key words: glial cell line-derived neurotrophic factor (GDNF), glutamate, neurological disorders, neuroprotection, Parkinson’s disease, preclinical studies, rasagiline, safinamide, selegiline, type-B monoamine oxidase (MAOB) inhibitors